DC in multiple myeloma immunotherapy

被引：13
作者：
Turtle, CJ
Brown, RD
Joshua, DE
Hart, DNJ
机构：
[1] Mater Med Res Inst, Dendrit Cell Lab, Brisbane, Qld 4101, Australia
[2] Royal Prince Alfred Hosp, Inst Haematol, Camperdown, NSW 2050, Australia
来源：
CYTOTHERAPY | 2004年 / 6卷 / 02期
关键词：
multiple myeloma; dendritic cells; immunotherapy; tumor-associated antigens;
D O I：
10.1080/14653240410005357
中图分类号：
Q813 [细胞工程];
学科分类号：
摘要：
Therapy for patients with multiple myeloma ( MM) is currently unsatisfactory and most patients eventually succumb to relapsed disease. DCs are a subset of leukocytes with the capacity to initiate and control the adaptive immune response against many cancers, including MM. In MM patients, in vivo DC function is often abnormal, however, it appears that it can be restored by in vitro manipulation. This has led to the development of DC immunotherapy for MM patients. We review the background research leading to the recognition of an anti-MM immune response, and discuss abnormalities in DC function, potential tumor-associated Ags, and the results of clinical trials of DC immunotherapy in MM patients.
引用
收藏
页码：128 / 137
页数：10
相关论文
共 82 条
[1]   CMRF44+dendritic cells from peripheral blood stem cell harvests of patients with myeloma as potential cellular vectors for idiotype vaccination [J].
Barrow, L ;
Brown, RD ;
Murray, A ;
Sze, DM ;
Pope, B ;
Gibson, J ;
Hart, D ;
Joshua, D .
LEUKEMIA & LYMPHOMA, 2003, 44 (12) :2117-2122
[2]   Lymphoid reconstitution after autologous PBSC transplantation with FACS-sorted CD34+ hematopoietic progenitors [J].
Bomberger, C ;
Singh-Jairam, M ;
Rodey, G ;
Guerriero, A ;
Yeager, AM ;
Fleming, WH ;
Holland, HK ;
Waller, EK .
BLOOD, 1998, 91 (07) :2588-2600
[3]   Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies [J].
Brossart, P ;
Heinrich, KS ;
Stuhler, G ;
Behnke, L ;
Reichardt, VL ;
Stevanovic, S ;
Muhm, A ;
Rammensee, HG ;
Kanz, L ;
Brugger, W .
BLOOD, 1999, 93 (12) :4309-4317
[4]  
Brossart P, 2001, CANCER RES, V61, P6846
[5]   The prognostic significance of T cell receptor beta gene rearrangements and idiotype-reactive T cells in multiple myeloma [J].
Brown, RD ;
Yuen, E ;
Nelson, M ;
Gibson, J ;
Joshua, D .
LEUKEMIA, 1997, 11 (08) :1312-1317
[6]   The expression of T cell related costimulatory molecules in multiple myeloma [J].
Brown, RD ;
Pope, B ;
Yuen, E ;
Gibson, J ;
Joshua, DE .
LEUKEMIA & LYMPHOMA, 1998, 31 (3-4) :379-384
[7]   Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-β1 and interleukin-10 [J].
Brown, RD ;
Pope, B ;
Murray, A ;
Esdale, W ;
Sze, DM ;
Gibson, J ;
Ho, PJ ;
Hart, D ;
Joshua, D .
BLOOD, 2001, 98 (10) :2992-2998
[8]   Dendritic cells derived from multiple myeloma patients efficiently internalize different classes of myeloma protein [J].
Butch, AW ;
Kelly, KA ;
Munshi, NC .
EXPERIMENTAL HEMATOLOGY, 2001, 29 (01) :85-92
[9]  
Camporeale A, 2003, CANCER RES, V63, P3688
[10]   Successful generation of sperm protein 17 (Sp17)-specific cytotoxic T lymphocytes from normal donors: Implication for tumor-specific adoptive immunotherapy following allogeneic stem cell transplantation for Sp17-positive multiple myeloma [J].
Chiriva-Internati, M ;
Wang, Z ;
Salati, E ;
Wroblewski, D ;
Lim, SH .
SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2002, 56 (04) :429-433
123456789